Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

SMB00958

Sigma-Aldrich

N-Desmethyl imatinib

≥95%

Sinonimo/i:

N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-(piperazin-1-ylmethyl)benzamide, N-Desmethylimatinib, N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)benzamide, CGP74588, Desmethyl Gleevec, Norimatinib

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C28H29N7O
Numero CAS:
404844-02-6
Peso molecolare:
479.58
Codice UNSPSC:
12352205
NACRES:
NA.77

Origine biologica

synthetic

Livello qualitativo

200

Grado

research grade

Saggio

≥95%

Forma fisica

solid

PM

479.58 g/mol

Condizioni di stoccaggio

(Tightly closed. Dry. Keep in a well -ventilated place. Keep locked up or in an area accessible only to qualified or authorized persons.)

tecniche

HPLC: suitable

Solubilità

ethanol: 0.20 mg/mL
DMF: 16 mg/mL

Temperatura di conservazione

2-8°C

InChI

1S/C28H29N7O/c1-20-4-9-24(17-26(20)34-28-31-12-10-25(33-28)23-3-2-11-30-18-23)32-27(36)22-7-5-21(6-8-22)19-35-15-13-29-14-16-35/h2-12,17-18,29H,13-16,19H2,1H3,(H,32,36)(H,31,33,34)
BQQYXPHRXIZMDM-UHFFFAOYSA-N

Descrizione generale

N-Desmethyl imatinib is a pharmacologically active metabolite of imatinib with long elimination half-life. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8.

Applicazioni

Application: Metabolomics research

Altre note

For additional information on our range of Biochemicals, please complete this form.

Pittogrammi

Health hazard
GHS08

Avvertenze

Danger

Indicazioni di pericolo

H341,H351,H360D,H362

Classi di pericolo

Carc. 2 - Lact. - Muta. 2 - Repr. 1B

Codice della classe di stoccaggio

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Hans-Peter Gschwind et al.
Drug metabolism and disposition: the biological fate of chemicals, 33(10), 1503-1512 (2005-07-12)
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male
Muhammad Suleman Khan et al.
Xenobiotica; the fate of foreign compounds in biological systems, 46(3), 278-287 (2015-07-15)
1. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8. The effect of CYP2C8*3 genotype on N-desmethyl imatinib formation was unknown. 2. We examined imatinib N-demethylation in human liver microsomes (HLMs) genotyped for CYP2C8*3, in CYP2C8*3/*3 pooled HLMs
Yuji Mukai et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1137, 121928-121928 (2019-12-27)
Therapeutic drug monitoring is important in patients taking BCR-ABL and Bruton's tyrosine kinase inhibitors (TKIs). Some TKI active metabolites with long elimination half-lives, such as dihydrodiol ibrutinib (DHI), N-desmethyl imatinib (N-DI), and N-desmethyl ponatinib (N-DP), have been characterized, indicating that

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.